Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
2(7%)
Results Posted
38%(5 trials)

Phase Distribution

Ph phase_2
7
25%
Ph early_phase_1
1
4%
Ph phase_4
6
21%
Ph phase_3
7
25%
Ph not_applicable
3
11%
Ph phase_1
3
11%

Phase Distribution

4

Early Stage

7

Mid Stage

13

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
1(3.7%)
Phase 1Safety & dosage
3(11.1%)
Phase 2Efficacy & side effects
7(25.9%)
Phase 3Large-scale testing
7(25.9%)
Phase 4Post-market surveillance
6(22.2%)
N/ANon-phased studies
3(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.7%

13 of 15 finished

Non-Completion Rate

13.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

28

all time

Status Distribution
Active(4)
Completed(13)
Terminated(2)
Other(9)

Detailed Status

Completed13
unknown9
Withdrawn2
Not yet recruiting2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
28
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.7%)
Phase 13 (11.1%)
Phase 27 (25.9%)
Phase 37 (25.9%)
Phase 46 (22.2%)
N/A3 (11.1%)

Trials by Status

withdrawn27%
recruiting14%
completed1346%
active_not_recruiting14%
unknown932%
not_yet_recruiting27%

Recent Activity

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT04547049Phase 3

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Active Not Recruiting
NCT06246786Early Phase 1

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Withdrawn
NCT06525948Phase 4

Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA

Not Yet Recruiting
NCT05692843Phase 4

Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response

Unknown
NCT04688021Phase 2

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Unknown
NCT04239859Phase 4

Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis

Not Yet Recruiting
NCT04537689Phase 4

Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

Recruiting
NCT04945096Phase 3

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Unknown
NCT04376528Phase 4

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Unknown
NCT04540926Phase 1

Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia

Unknown
NCT02370550Phase 4

Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome

Unknown
NCT02487069Not Applicable

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Completed
NCT03026946Phase 3

Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema

Unknown
NCT00167583Phase 3

Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)

Completed
NCT00176865Phase 2

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed
NCT00303667Phase 1

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Completed
NCT00114777Phase 3

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Completed
NCT01843348Phase 3

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

Completed
NCT02203422Phase 3

A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)

Withdrawn
NCT02706470Phase 2

Use of Cyclosporin A for the Treatment of Recurrent Miscarriage

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
28